Molecular Diagnostics Market Set for Steady Expansion by 2032, Driven by Innovation and Growing Surgical Volumes | DelveInsight

The Molecular Diagnostics Market was valued at USD 9.56 billion in 2024 and is projected to grow at a CAGR of 9.21% during the forecast period, reaching USD 16.12 billion by 2032. This growth is primarily driven by the rising incidence of infectious diseases such as HIV, Hepatitis B and C, Influenza, and human papillomavirus (HPV). Additionally, the launch of innovative and advanced diagnostic solutions by leading molecular diagnostics companies is expected to further propel market expansion from 2024 to 2032.

DelveInsight's Molecular Diagnostics Market Insights report provides the current and forecast market analysis, individual leading Molecular Diagnostics companies' market shares, challenges, Molecular Diagnostics market drivers, barriers, and trends, and key Molecular Diagnostics companies in the market.

Request for a sample report @ https://www.delveinsight.com/report-store/molecular-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Molecular Diagnostics Market Report
• The Molecular Diagnostics market is projected to grow at a moderate CAGR from 2025 to 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global Molecular Diagnostics market during the forecast period.
• Notable Molecular Diagnostics companies such as Hoffmann-La Roche Ltd., Hologic, Inc., bioMérieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and several others are currently operating in the Molecular Diagnostics market.
In November 2021, Roche unveiled the cobas® 5800 System, a new molecular diagnostic instrument designed for laboratories in countries recognizing the CE mark.
In October 2021, Hologic launched the Novodiag system in Europe, a molecular diagnostic platform that enables on-demand testing. It integrates real-time PCR with microarray technology to detect multiple pathogens from a single sample.
In March 2021, Materials and Machines Corporation (MatMaCorp) released the MY Real-Time Analyzer (MYRTA), a portable device capable of performing PCR amplification and real-time fluorescent detection.


To read more about the latest highlights related to the Molecular Diagnostics market, get a snapshot of the key highlights entailed in the Global Molecular Diagnostics Market Report https://www.delveinsight.com/sample-request/molecular-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Molecular Diagnostics Overview

Molecular diagnostics is a rapidly growing field focused on analyzing biological markers in the genome and proteome to diagnose and monitor diseases. It plays a crucial role in detecting infectious diseases, genetic disorders, and cancers by identifying specific DNA, RNA, or protein signatures. Techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and microarray analysis enable highly sensitive and precise testing.

The demand for molecular diagnostics has surged due to the increasing prevalence of infectious diseases like HIV, hepatitis, influenza, and human papillomavirus (HPV), as well as the growing need for personalized medicine and targeted therapies. Innovations from key industry players are continually enhancing test accuracy, speed, and accessibility.

Molecular diagnostics assist clinicians in early disease detection, monitoring treatment effectiveness, and guiding therapy choices, thereby improving patient outcomes and healthcare efficiency. The market is expected to expand significantly in the coming years, driven by technological advancements and rising awareness of its clinical benefits.

Molecular Diagnostics Market Insights

North America is anticipated to capture a substantial share of the molecular diagnostics market revenue during the forecast period from 2024 to 2032. This regional dominance is attributed to several key factors, including the increasing incidence of cancer and infectious diseases such as tuberculosis, advancements in product development, and the strong presence of major manufacturers. According to the Global Cancer Observatory (2024), approximately 3.83 million new cancer cases are expected to be diagnosed in North America by 2045. Molecular diagnostics play a crucial role in oncology by detecting genetic mutations, supporting personalized treatment plans, and tracking disease progression through technologies like liquid biopsy and companion diagnostics.

Additionally, the Public Health Agency of Canada (2024) reported 1,971 active tuberculosis cases in Canada in 2022. Molecular diagnostic tools offer rapid and accurate detection of Mycobacterium tuberculosis and help identify drug-resistant strains, enabling faster diagnosis and improved treatment decisions. The presence of leading industry players and their strategic initiatives, along with supportive regulatory efforts aimed at enhancing product development, are expected to further drive market growth in the region.


To know more about why North America is leading the market growth in the Molecular Diagnostics market, get a snapshot of the Molecular Diagnostics Market Outlook https://www.delveinsight.com/report-store/molecular-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Molecular Diagnostics Market Dynamics

According to the World Health Organization (WHO) 2024 data, approximately 39 million people worldwide were living with HIV in 2022, with around 37.5 million being adults (aged 15 and above) and about 1.5 million being children under the age of 15. Molecular diagnostics play a vital role in HIV care by enabling early detection, monitoring viral loads, and identifying drug resistance mutations. These diagnostic tools are essential for evaluating treatment effectiveness, guiding therapy decisions, and minimizing transmission, especially among high-risk groups like children and adults.

Additionally, WHO 2024 data reported that 304 million individuals globally were living with hepatitis B and C in 2022-254 million with hepatitis B and 50 million with hepatitis C. Molecular diagnostics are crucial for managing these infections, as they facilitate early and precise detection of the viruses. Techniques like PCR help identify viral DNA or RNA in blood samples, which allows healthcare providers to confirm active infections, track viral loads, and evaluate treatment outcomes.


Molecular Diagnostics Market Drivers:
The molecular diagnostics market is witnessing substantial growth driven by the rising prevalence of infectious diseases such as HIV, Hepatitis B and C, Influenza, and human papillomavirus (HPV). Additionally, the launch of new and innovative products by leading molecular diagnostics companies is expected to further propel the market from 2024 to 2032.


Get a sneak peek at the Molecular Diagnostics market dynamics @ https://www.delveinsight.com/sample-request/molecular-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Coverage: Global
Study Period: 2022 to 2032
Key Molecular Diagnostics Companies: Hoffmann-La Roche Ltd., Hologic, Inc., bioMérieux SA, Abbott, QIAGEN, BD, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher, Myriad Genetics, Inc., Agilent Technologies Inc., Illumina Inc., DiaSorin Inc., MDxHealth, Genetic Signatures, Biocartis, Exact Sciences Corporation, Amoy Diagnostics Co. Ltd., Molbio Diagnostics Pvt. Ltd., Savyon Diagnostics, and others.

Which MedTech key players in the Molecular Diagnostics market are set to emerge as the trendsetter, explore @ Molecular Diagnostics Companies https://www.delveinsight.com/report-store/molecular-diagnostics-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Table of Contents
1. Molecular Diagnostics Market Report Introduction
2. Molecular Diagnostics Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Molecular Diagnostics Market Key Factors Analysis
6. Molecular Diagnostics Market Porter's Five Forces Analysis
7. Molecular Diagnostics Market Layout
8. Molecular Diagnostics Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.